Compare SWVL & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWVL | PASG |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United Arab Emirates | United States |
| Employees | N/A | 27 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 14.8M |
| IPO Year | 2021 | 2020 |
| Metric | SWVL | PASG |
|---|---|---|
| Price | $5.55 | $4.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.5M | 11.6K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $3.29 |
| 52 Week High | $5.50 | $20.00 |
| Indicator | SWVL | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 89.91 | 52.53 |
| Support Level | $1.34 | $4.27 |
| Resistance Level | N/A | $4.95 |
| Average True Range (ATR) | 0.49 | 0.29 |
| MACD | 0.36 | 0.03 |
| Stochastic Oscillator | 87.44 | 52.24 |
Swvl Holdings Corp is a technology-driven mobility company providing mass transit solutions. It currently has two offerings: business-to-consumer (B2C) and B2B (marketed as Swvl Business). The company's B2C business utilizes its platform to provide riders with a network of minibuses and other vehicles that operate on fixed and semi-fixed routes throughout and between different cities. Riders can book available seats on vehicles to commute within a city. The Swvl Business caters to corporate customers (as well as schools and municipalities), providing them with transportation solutions for their employees and students. This business also offers transportation management software to clients who operate their own fleet. Geographically, the company generates maximum revenue from Egypt.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.